Skip to content

CJD (Creutzfeldt-Jakob Disease) Quinacrine Study

Novel Therapeutics For Prion Diseases: A Randomized, Double-blinded, Placebo-controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob Disease

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00183092
Enrollment
69
Registered
2005-09-16
Start date
2005-04-30
Completion date
2012-06-30
Last updated
2014-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Creutzfeldt-Jakob Disease

Keywords

dementia, spongiform encephalopathy, nervous system disorder, acridine, prion, neuropharmacologic agent

Brief summary

The purpose of this clinical trial is to determine the effectiveness of the medication quinacrine on survival in sporadic Creutzfeldt-Jakob disease (sCJD).

Detailed description

Creutzfeldt-Jakob disease (CJD)is a rapidly progressive, invariably fatal and untreatable neurodegenerative disease with a mean duration of about eight months. Beyond the debilitating cognitive and motor deficits that accompany CJD, the difficulty in treating behavioral and mood disturbances and the rapidity of its course compound its tragedy. Recent results from experiments show that, at physiological concentrations, the anti-malarial drug quinacrine permanently clears abnormal prion proteins from cell culture. The demonstrated efficacy of quinacrine in cell culture, its relative safety and well known side-effects in the clinical setting, and the universal fatality of CJD justify quinacrine as an immediate candidate for the treatment of CJD. The purpose of this clinical trial is to determine the efficacy of the medication quinacrine on survival in sporadic CJD (sCJD). This will be accomplished by bringing approximately 60 patients with probable or definite sCJD over approximately three years to UCSF for evaluation and initiation of a randomized, double-blinded, placebo-controlled (delayed treatment start) treatment study of quinacrine. Each patient will have a 50:50 chance of being placed on quinacrine or placebo upon study enrollment; however, all patients will be offered quinacrine after two months. Prior to study enrollment, patients will have a comprehensive clinical assessment to confirm the diagnosis of sCJD. Participants will come to UCSF for initial evaluation, potential study enrollment and, if possible, return to UCSF for follow-up at two and twelve months. Patients will receive telephone follow-up (every 2 weeks for the first two months and monthly thereafter) and local blood and testing to monitor for possible medication toxicity.

Interventions

100mg by mouth three times a day

DRUGPlacebo

100mg by mouth three times a day

Sponsors

National Institute on Aging (NIA)
CollaboratorNIH
University of California, San Francisco
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of probable or definite sCJD: Definite--biopsy confirmed sCJD; Probable--a progressive dementia with either a typical EEG or a typical MRI consistent with sCJD, and at least two of the following clinical features: myoclonus, pyramidal or extrapyramidal signs, visual symptoms, cerebellar signs, akinetic mutism, other focal higher cortical neurologic signs (e.g. neglect, apraxia, aphasia) * 18 years of age or older * Able to swallow * Able to follow simple one-step commands * Have had a brain MRI within 6 months and an EEG within 3 months ruling out other etiologies such as masses, strokes, or non-convulsive status epilepticus * Consent to autopsy in the event of their death during or after the study

Exclusion criteria

* History of other significant or life-threatening disease, including: cancer; end-stage liver or renal disease; severe heart disease * History of other disease requiring regular supportive care * Liver disease * Active alcoholism * Bone marrow suppression * Severe hypotension * Severe psoriasis * Poorly controlled diabetes * Women who are pregnant or breast-feeding * Men, or women of childbearing age, not practicing reliable contraception * Serious allergies to quinacrine or other acridines * Current or recent use of quinacrine (within 6 months) * \< 18 years of age * Any other contraindication to taking quinacrine * Genetic form of prion disease is identified prior to study enrollment * Current use of anti-arrhythmics (at discretion of investigator) * G6PD (Glucose 6-Phosphate Dehydrogenase) deficiency (at discretion of investigator)

Design outcomes

Primary

MeasureTime frameDescription
Primary SurvivalRandomization to Month-2Participants alive after 2 months on study treatment

Secondary

MeasureTime frameDescription
Barthel Score Change After 2 Monthsbaseline, 2 monthsAn ordinal scale used to measure performance in activities of daily living. Scores range from 0 (worst, fully dependent) to 100 (best, independent); higher score associated with a greater likelihood of being able to live at home with a degree of independence following discharge from hospital. 10 individual items are scored and summed to derive the overall Barthel index score. Each item may be scored 0, 5, 10 or 15; not all items use the full range of 4 possible values. The amount of time and physical assistance required to perform each item are considered in scoring each item. For subjects unable to return for month-2 visit, Barthel Index was performed via telephone.
Change in Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB) After 2 MonthsBaseline, 2 monthsClinical Dementia Rating Scale Sum of Boxes (CDRS-SB). The CDR is obtained through semistructured interviews of patients and informants, and cognitive functioning is rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a 5-point scale of functioning: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment (personal care is scored on a 4-point scale without a 0.5 rating available). The global CDR score is computed via an algorithm. The CDR-SB score is obtained by summing each of the domain box scores, with scores ranging from 0 to 18. A higher value and/or positive change is worse. For subjects unable to return for month-2 visit, CDRS-SB was performed via telephone.
Change in Rankin Score After 2 MonthsBaseline, 2 monthsThe scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms. 1. \- No significant disability. Able to carry out all usual activities, despite some symptoms. 2. \- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. \- Moderate disability. Requires some help, but able to walk unassisted. 4. \- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. \- Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. \- Dead. For subjects unable to return for the 2-month visit, Rankin score was assessed via telephone.
Change in Mini-Mental State Examination (MMSE) After 2 MonthsBaseline to Month-2The mini-mental state examination (MMSE) is a brief 30-point questionnaire that is used to screen for cognitive impairment. In about 10 minutes it samples functions including arithmetic, memory and orientation. A score greater than or equal to 25 points (out of 30) indicates a normal cognition. Lower scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-24 points) cognitive impairment. Low to very low scores correlate closely with the presence of dementia, although other mental disorders can also lead to abnormal findings on MMSE testing.
Change in Phonemic Fluency (Words Beginning With Letter D)Baseline, 2 monthsVerbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (words beginning with letter D) is phonemic. Higher scores indicate better cognition.
Change in Semantic Verbal Fluency (Naming Animals)Baseline, 2 monthsVerbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (naming animals) is semantic. Higher scores indicate better cognition.
ADAS-Cog Change After 2 Months Among SurvivorsBaseline, 2 monthsADAS-cog measures cognitive performance by combining ratings of 11 components (word recall, word recognition, constructional praxis, orientation, naming objects and fingers, commands, ideational praxis, remembering instruction, spoken language, word finding, comprehension) representing six areas of cognition: memory; language; orientation to time, place and person; construction of simple designs and planning; and performing simple behaviors in pursuit of a basic, predefined goal. Seven components are scored as the 'number incorrect'. For example, in the commands component, the number of five commands performed incorrectly (range: 0-5). Four components are scored from 0 (no limitations) to 5 (max limitations) as the examiner's perception of remembering instructions, spoken language ability, word finding and comprehension. Component scores are summed into a total ADAS-cog score ranging from 0-75, with low scores indicating better cognitive performance.

Countries

United States

Participant flow

Recruitment details

Enrollment began in April 2005 and ended in January 2009. Subjects came from across the USA, as well as Canada, with a plurality from California, and enrolled at one U.S. clinical site (University of California, San Francisco).

Pre-assignment details

425 patients referred; 69 subjects consented/enrolled; 54 subjects eligible/randomized; 3 randomized subjects identified as carriers of PrP (prion protein) gene mutations as determined by analysis of sequence variability of the bovine prion protein gene (PRNP) and excluded from analyses.

Participants by arm

ArmCount
Placebo
Placebo : 100mg by mouth three times a day
28
Quinacrine
Quinacrine : 100mg by mouth three times a day
23
Total51

Baseline characteristics

CharacteristicPlaceboQuinacrineTotal
Age, Continuous64.4 years
FULL_RANGE 10.9
60.5 years
FULL_RANGE 8
62.5 years
Region of Enrollment
United States
28 participants23 participants51 participants
Sex: Female, Male
Female
9 Participants11 Participants20 Participants
Sex: Female, Male
Male
19 Participants12 Participants31 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —
other
Total, other adverse events
9 / 289 / 2316 / 24
serious
Total, serious adverse events
14 / 2813 / 2314 / 24

Outcome results

Primary

Primary Survival

Participants alive after 2 months on study treatment

Time frame: Randomization to Month-2

ArmMeasureValue (NUMBER)
PlaceboPrimary Survival19 participants
QuinacrinePrimary Survival13 participants
p-value: 0.4395% CI: [0.58, 3.53]Regression, Cox
Secondary

ADAS-Cog Change After 2 Months Among Survivors

ADAS-cog measures cognitive performance by combining ratings of 11 components (word recall, word recognition, constructional praxis, orientation, naming objects and fingers, commands, ideational praxis, remembering instruction, spoken language, word finding, comprehension) representing six areas of cognition: memory; language; orientation to time, place and person; construction of simple designs and planning; and performing simple behaviors in pursuit of a basic, predefined goal. Seven components are scored as the 'number incorrect'. For example, in the commands component, the number of five commands performed incorrectly (range: 0-5). Four components are scored from 0 (no limitations) to 5 (max limitations) as the examiner's perception of remembering instructions, spoken language ability, word finding and comprehension. Component scores are summed into a total ADAS-cog score ranging from 0-75, with low scores indicating better cognitive performance.

Time frame: Baseline, 2 months

Population: Subjects still alive and able to tolerate cognitive testing at Month 2 visit.

ArmMeasureValue (MEAN)
PlaceboADAS-Cog Change After 2 Months Among Survivors13.0 units on a scale
QuinacrineADAS-Cog Change After 2 Months Among Survivors12.6 units on a scale
Comparison: The difference between change scores, adjusted for Month-0 performance. Positive adjusted differences indicate greater adjusted change (worsening) in the placebo group; negative indicate greater adjusted changed (worsening) in the quinacrine group.p-value: 0.92ANCOVA
Secondary

Barthel Score Change After 2 Months

An ordinal scale used to measure performance in activities of daily living. Scores range from 0 (worst, fully dependent) to 100 (best, independent); higher score associated with a greater likelihood of being able to live at home with a degree of independence following discharge from hospital. 10 individual items are scored and summed to derive the overall Barthel index score. Each item may be scored 0, 5, 10 or 15; not all items use the full range of 4 possible values. The amount of time and physical assistance required to perform each item are considered in scoring each item. For subjects unable to return for month-2 visit, Barthel Index was performed via telephone.

Time frame: baseline, 2 months

Population: One surviving subject in the quinacrine arm did not attend the 2-month visit and was lost-to-followup; for a second surviving subject in the quinacrine arm, the Barthel Index was inadvertently not performed at the 2-month visit.

ArmMeasureValue (MEAN)
PlaceboBarthel Score Change After 2 Months-23.2 units on a scale
QuinacrineBarthel Score Change After 2 Months-13.2 units on a scale
Comparison: The difference between scores, adjusted for Month-0 performance.p-value: 0.36Quade's rank analysis of covariance
Secondary

Change in Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB) After 2 Months

Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB). The CDR is obtained through semistructured interviews of patients and informants, and cognitive functioning is rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a 5-point scale of functioning: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment (personal care is scored on a 4-point scale without a 0.5 rating available). The global CDR score is computed via an algorithm. The CDR-SB score is obtained by summing each of the domain box scores, with scores ranging from 0 to 18. A higher value and/or positive change is worse. For subjects unable to return for month-2 visit, CDRS-SB was performed via telephone.

Time frame: Baseline, 2 months

Population: For subjects still alive at month 2 and assessed at the 2-month visit or via telephone

ArmMeasureValue (MEAN)
PlaceboChange in Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB) After 2 Months3.2 units on a scale
QuinacrineChange in Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB) After 2 Months0.3 units on a scale
Comparison: The difference between change scores, adjusted for Month-0 performance. Positive adjusted differences indicate greater adjusted change (worsening) in the placebo group; negative indicate greater adjusted changed (worsening) in the quinacrine group.p-value: 0.01Quade's rank analysis of covariance
Secondary

Change in Mini-Mental State Examination (MMSE) After 2 Months

The mini-mental state examination (MMSE) is a brief 30-point questionnaire that is used to screen for cognitive impairment. In about 10 minutes it samples functions including arithmetic, memory and orientation. A score greater than or equal to 25 points (out of 30) indicates a normal cognition. Lower scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-24 points) cognitive impairment. Low to very low scores correlate closely with the presence of dementia, although other mental disorders can also lead to abnormal findings on MMSE testing.

Time frame: Baseline to Month-2

Population: Subjects still alive, who attended the month-2 visit and were willing and able to tolerate cognitive testing. 1 subject in each arm did attend the 2-month visit but did not cooperate fully with the MMSE, which was therefore not scored.

ArmMeasureValue (MEAN)
PlaceboChange in Mini-Mental State Examination (MMSE) After 2 Months-6.9 units on a scale
QuinacrineChange in Mini-Mental State Examination (MMSE) After 2 Months-3.9 units on a scale
Comparison: The difference between change scores, adjusted for Month-0 performance. Positive adjusted differences indicate greater adjusted change (worsening) in the placebo group; negative indicate greater adjusted changed (worsening) in the quinacrine group.p-value: 0.54ANCOVA
Secondary

Change in Phonemic Fluency (Words Beginning With Letter D)

Verbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (words beginning with letter D) is phonemic. Higher scores indicate better cognition.

Time frame: Baseline, 2 months

Population: Subject still alive and able to tolerate cognitive testing at month 2 visit

ArmMeasureValue (MEAN)
PlaceboChange in Phonemic Fluency (Words Beginning With Letter D)-2.4 number of words generated
QuinacrineChange in Phonemic Fluency (Words Beginning With Letter D)-2.2 number of words generated
Comparison: The difference between change scores, adjusted for Month-0 performance. Positive adjusted differences indicate greater adjusted change (worsening) in the placebo group; negative indicate greater adjusted changed (worsening) in the quinacrine group.p-value: 0.71ANCOVA
Secondary

Change in Rankin Score After 2 Months

The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms. 1. \- No significant disability. Able to carry out all usual activities, despite some symptoms. 2. \- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. \- Moderate disability. Requires some help, but able to walk unassisted. 4. \- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. \- Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. \- Dead. For subjects unable to return for the 2-month visit, Rankin score was assessed via telephone.

Time frame: Baseline, 2 months

Population: For subjects still alive at month 2 and assessed at the 2-month visit or via telephone

ArmMeasureValue (MEAN)
PlaceboChange in Rankin Score After 2 Months0.8 units on a scale
QuinacrineChange in Rankin Score After 2 Months0.3 units on a scale
Comparison: The difference between change scores, adjusted for Month-0 performance. Positive adjusted differences indicate greater adjusted change (worsening) in the placebo group; negative indicate greater adjusted changed (worsening) in the quinacrine group.p-value: 0.03Quade's rank analysis of covariance
Secondary

Change in Semantic Verbal Fluency (Naming Animals)

Verbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (naming animals) is semantic. Higher scores indicate better cognition.

Time frame: Baseline, 2 months

Population: Subjects still alive and able to tolerate cognitive testing at month 2 visit.

ArmMeasureValue (MEAN)
PlaceboChange in Semantic Verbal Fluency (Naming Animals)-3.2 number of words generated
QuinacrineChange in Semantic Verbal Fluency (Naming Animals)-2.2 number of words generated
Comparison: The difference between change scores, adjusted for Month-0 performance. Positive adjusted differences indicate greater adjusted change (worsening) in the placebo group; negative indicate greater adjusted change (worsening) in the quinacrine group.p-value: 0.7ANCOVA

Source: ClinicalTrials.gov · Data processed: Mar 22, 2026